Botulinum Toxin A (Dysport®) in der Behandlung myofaszialer Schmerzen des oberen Rückens und des Halses: Vergleich der Effektivität bei individueller und bei standardisierter Auswahl der Injektionsareale

Hartmut Göbel(Clinical Research Center Kiel), R. Benecke(Children's Hospital of Philadelphia), G Reichel(Paracelsus-Kliniken), Harald Hefter(Heinrich Heine University Düsseldorf), A. Heinze(Clinical Research Center Kiel)
Klinische Neurophysiologie
December 1, 2007
10.1055/s-2007-1032229
Cited by 0

Related Papers

Genome-wide meta-analysis identifies new susceptibility loci for migraine
|Nature Genetics|2013|415
Genome-wide association analysis identifies susceptibility loci for migraine without aura
|Nature Genetics|2012|353
Transcranial magnetic stimulation of the human brain: responses in muscles supplied by cranial nerves
|Experimental Brain Research|1988|304
On the origin of the postexcitatory inhibition seen after transcranial magnetic brain stimulation in awake human subjects
|Experimental Brain Research|1993|303
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of Three Doses of Botulinum Toxin Type A (Dysport) With Placebo in Upper Limb Spasticity After Stroke
|Stroke|2000|298